TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling

Hepatology

Volumn 66, Issue 4, 2017, Pages 1197-1218

  Masyuk, Tatyana V ^a   Masyuk, Anatoliy I ^a   Lorenzo Pisarello, Maria ^a   Howard, Brynn N ^a   Huang, Bing Q ^a   Lee, Pui Yuen ^a   Fung, Xavier ^a   Sergienko, Eduard ^b   Ardecky, Robert J ^b   Chung, Thomas D Y ^a   Pinkerton, Anthony B ^b   LaRusso, Nicholas F ^a  

^a MAYO CLINIC   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 TOLYL 5 CHLORO 2 [ETHYLSULFONYL]PYRIMIDINE 4 CARBOXYLATE; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; MITOGEN ACTIVATED PROTEIN KINASE; OLEANOLIC ACID; PASIREOTIDE; PROTEIN INHIBITOR; SHORT HAIRPIN RNA; TAKEDA G PROTEIN RECEPTOR 5; TAUROLITHOCHOLIC ACID; UNCLASSIFIED DRUG; DZIP1 PROTEIN, HUMAN; GPBAR1 PROTEIN, RAT; M-TOLYL 5-CHLORO-2-(ETHYLSULFONYL)PYRIMIDINE-4-CARBOXYLATE; PYRIMIDINE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SOMATOSTATIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAMP SIGNALING; CELL MATURATION; CELL PROLIFERATION; CHOLANGIOCYTE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LIVER POLYCYSTIC DISEASE; MALE; NONHUMAN; PCK RAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUMOR GROWTH; WESTERN BLOTTING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; CYSTS; DRUG EFFECTS; GENETICS; KIDNEY POLYCYSTIC DISEASE; LIVER DISEASES; METABOLISM; MOUSE; PRECLINICAL STUDY; PRIMARY CELL CULTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL PROLIFERATION; CYCLIC AMP; CYSTS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; LIVER DISEASES; MICE; OLEANOLIC ACID; POLYCYSTIC KIDNEY DISEASES; PRIMARY CELL CULTURE; PYRIMIDINES; RATS; RECEPTORS, G-PROTEIN-COUPLED; SOMATOSTATIN;

EID: 85028344145     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29284     Document Type: Article

References (41)

1. Wills ES, Roepman R, Drenth JP. Polycystic liver disease: ductal plate malformation and the primary cilium. Trends Mol Med 2014;20:261-270.
2. Masyuk TV, Masyuk AI, La Russo NF. Therapeutic targets in polycystic liver disease. Curr Drug Targets 2017;18(8):950–957.
3. Perugorria MJ, Masyuk TV, Marin JJ, Marzioni M, Bujanda L, LaRusso NF, et al. Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol 2014;11:750-761. doi: 10.1038/nrgastro.2014.155.
4. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 2007;132:1104-1116.
5. Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF. The cAMP effectors Epac and protein kinase A (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009;49:160-174.
6. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Masyuk AI, Gradilone SA, et al. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology 2012;142:622-633.
7. Banales JM, Masyuk TV, Bogert PS, Huang BQ, Gradilone SA, Lee SO, et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008;173:1637-1646.
8. Choi YH, Suzuki A, Hajarnis S, Ma Z, Chapin HC, Caplan MJ, et al. Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc Natl Acad Sci USA 2011;108:10679-10684.
9. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 2013;58:409-421.
10. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21:1052-1061.
11. Larusso NF, Masyuk TV, Hogan MC. Polycystic liver disease: the benefits of targeting cAMP. Clin Gastroenterol Hepatol 2016;14:1031-1034.
12. Neijenhuis MK, Gevers TJ, Nevens F, Hogan MC, Torres VE, Kievit W, et al. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials. Aliment Pharmacol Ther 2015;42:591-598.
13. Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis 2014;46:302-312.
14. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014;11:55-67.
15. Keitel V, Reich M, Haussinger D. TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis? Clin Rev Allergy Immunol 2015;48:218-225.
16. Keitel V, Haussinger D. TGR5 in cholangiocytes. Curr Opin Gastroenterol 2013;29:299-304.
17. Hodge RJ, Nunez DJ. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype? Diabetes Obes Metab 2016;18:439-443.
18. Masyuk AI, Huang BQ, Radtke BN, Gajdos GB, Splinter PL, Masyuk TV, et al. Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am J Physiol Gastrointest Liver Physiol 2013;304:G1013-G1024.
19. Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Saez E, et al. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol 2015;63:952-961.
20. Hong J, Behar J, Wands J, Resnick M, Wang LJ, DeLellis RA, et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 2010;59:170-180.
21. Reich M, Deutschmann K, Sommerfeld A, Klindt C, Kluge S, Kubitz R, et al. TGR5 is essential for bile acid–dependent cholangiocyte proliferation in vivo and in vitro. Gut 2016;65:487-501.
22. Cao W, Tian W, Hong J, Li D, Tavares R, Noble L, et al. Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 2013;304:G322-G327.
23. Carino A, Graziosi L, D'Amore C, Cipriani S, Marchiano S, Marino E, et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget 2016;7:61021-61035.
24. Piotrowski DW, Futatsugi K, Warmus JS, Orr ST, Freeman-Cook KD, Londregan AT, et al. Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists. ACS Med Chem Lett 2013;4:63-68.
25. Evans KA, Budzik BW, Ross SA, Wisnoski DD, Jin J, Rivero RA, et al. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J Med Chem 2009;52:7962-7965.
26. Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids. J Vis Exp 2011; doi: 10.3791/2720.
27. Ware MJ, Colbert K, Keshishian V, Ho J, Corr SJ, Curley SA, et al. Generation of homogenous three-dimensional pancreatic cancer cell spheroids using an improved hanging drop technique. Tissue Eng Part C Methods 2016;22:312-321.
28. Jeong DW, Kim YH, Kim HH, Ji HY, Yoo SD, Choi WR, et al. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats. Biopharm Drug Dispos 2007;28:51-7.
29. Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J 2006;398:423-430.
30. Woollard JR, Punyashtiti R, Richardson S, Masyuk TV, Whelan S, Huang BQ, et al. A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. Kidney Int 2007;72:328-336.
31. Alpini G, Glaser SS, Ueno Y, Rodgers R, Phinizy JL, Francis H, et al. Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid–regulated ductal secretion. Gastroenterology 1999;116:179-186.
32. Casaburi I, Avena P, Lanzino M, Sisci D, Giordano F, Maris P, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle 2012;11:2699-2710.
33. Chen MC, Chen YL, Wang TW, Hsu HP, Lai MD. Membrane bile acid receptor TGR5 predicts good prognosis in ampullary adenocarcinoma patients with hyperbilirubinemia. Oncol Rep 2016;36:1997-2008.
34. Jensen DD, Godfrey CB, Niklas C, Canals M, Kocan M, Poole DP, et al. The bile acid receptor TGR5 does not interact with beta-arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. J Biol Chem 2013;288:22942-22960.
35. Jiang B, Zhao S, Tao Z, Wen J, Yang Y, Zheng Y, et al. Controlled bile acid exposure to oesophageal mucosa causes up-regulation of nuclear gamma-H2AX possibly via iNOS induction. Biosci Rep 2016;36:e00357.
36. Zhou H, Zhou S, Gao J, Zhang G, Lu Y, Owyang C. Upregulation of bile acid receptor TGR5 and nNOS in gastric myenteric plexus is responsible for delayed gastric emptying after chronic high-fat feeding in rats. Am J Physiol Gastrointest Liver Physiol 2015;308:G863-G873.
37. Lopez-Garcia S, Castaneda-Sanchez JI, Jimenez-Arellanes A, Dominguez-Lopez L, Castro-Mussot ME, Hernandez-Sanchez J, et al. Macrophage activation by ursolic and oleanolic acids during mycobacterial infection. Molecules 2015;20:14348-14364.
38. Gradilone SA, Habringer S, Masyuk TV, Howard BN, Masyuk AI, Larusso NF. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am J Pathol 2014;184:600-608.
39. Masyuk TV, Huang BQ, Ward CJ, Masyuk AI, Yuan D, Splinter PL, et al. Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology 2003;125:1303-1310.
40. Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ, et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein–coupled bile acid receptors. Endocrinology 2015;156:3961-3970.
41. Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology 2007;133:244-255.